Related references
Note: Only part of the references are listed.A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Marie Sebert et al.
HAEMATOLOGICA (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Jan Philipp Bewersdorf et al.
LEUKEMIA (2019)
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
Emilia Scalzulli et al.
ANNALS OF HEMATOLOGY (2019)
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guillermo Garcia-Manero et al.
LANCET HAEMATOLOGY (2019)
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Amer M. Zeidan et al.
ANNALS OF HEMATOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
Andrew H. Wei et al.
BLOOD (2019)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Guillermo Garcia-Manero et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2019)
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Uma Borate et al.
BLOOD (2019)
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
Amer M. Zeidan et al.
BLOOD (2019)
Azacitidine in Lower-Risk Myelodysplastic Syndromes: AMeta-Analysis of Data from Prospective Studies
Rami Komrokji et al.
ONCOLOGIST (2018)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2018)
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury
Yunwen Yang et al.
CLINICAL SCIENCE (2018)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
LEUKEMIA (2018)
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Amer M. Zeidan et al.
BLOOD CANCER JOURNAL (2018)
Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
Andrea Kuendgen et al.
Oncotarget (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Good news for patients with myelodysplastic syndromes and thrombocytopenia
Moshe Mittelman
LANCET HAEMATOLOGY (2018)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Pierre Fenaux et al.
BLOOD (2018)
PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Aaron T. Gerds et al.
BLOOD (2018)
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study
Emanuele Angelucci et al.
BLOOD (2018)
Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Kelly S. Chien et al.
BLOOD (2018)
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study
Courtney D. DiNardo et al.
BLOOD (2018)
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Guillermo Montalban-Bravo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Christian Scharenberg et al.
HAEMATOLOGICA (2017)
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Christian Scharenberg et al.
HAEMATOLOGICA (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2017)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Maximilian Stahl et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
Hee Sue Park et al.
ANNALS OF LABORATORY MEDICINE (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
Moreno Festuccia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Teresa Mortera-Blanco et al.
BLOOD (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A. Toma et al.
LEUKEMIA (2016)
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M. Zeidan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
M. Mossner et al.
LEUKEMIA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)
Eytan M. Stein et al.
BLOOD (2016)
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Ronan T. Swords et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CLINICAL CANCER RESEARCH (2015)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
Rajasekhar N. V. S. Suragani et al.
NATURE MEDICINE (2014)
Lenalidomide Performance in the Real World Patterns of Use and Effectiveness in a Medicare Population With Myelodysplastic Syndromes
Amer M. Zeidan et al.
CANCER (2013)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab
Ankur R. Parikh et al.
SEMINARS IN HEMATOLOGY (2012)
Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).
Sophie Park et al.
BLOOD (2012)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
ChunKang Chang et al.
BLOOD (2007)
Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: A systematic review and meta-analysis
Susan D. Ross et al.
ONCOLOGIST (2007)
Share Paper
